Schnorbach Marie-Therese, Kruis Wolfgang
Evangelisches Krankenhaus Kalk, Köln, Germany.
Z Gastroenterol. 2021 Nov;59(11):1173-1188. doi: 10.1055/a-1174-0670. Epub 2020 Aug 31.
The prevalence of inflammatory bowel disease (IBD) in Germany is rising. Due to a disease onset at a young age, direct and indirect costs are important. The aim of the present study is to provide a comprehensive presentation of existing healthcare costs for these diseases in Germany and to compare them by inflation adjustments for 2018.
Performing a systematic literature search, monetary costs were extracted from German and English literature. Quality and relevance of the studies were assessed with a checklist.
The average outpatient cost for inflammatory bowel disease amounts between 18 and 87 Euro/pat/30 days, the average inpatient cost was between 1026 and 9083 Euro/case. Depending on the type of calculation, biologicals cause different amounts of cost. Few data are available for direct medical 82 and 618 Euro/pat/30 days, direct non-medical 63 and 84 Euro/pat/30 days and indirect costs 463 and 3493 Euro/pat/30 days. The total costs are about 533 Euro/pat/30 days, related to one year 6485 Euro/pat.
For the first time, it is possible to compare existing medical costs for IBD in Germany. Current studies feature very heterogeneous methods and study populations of IBD. Depending on the collective, the total costs are up to 6485 Euro/patient/year.
德国炎症性肠病(IBD)的患病率正在上升。由于该病发病年龄较轻,直接和间接成本都很重要。本研究的目的是全面介绍德国这些疾病现有的医疗成本,并通过2018年的通胀调整进行比较。
进行系统的文献检索,从德语和英语文献中提取货币成本。用一份清单评估研究的质量和相关性。
炎症性肠病的平均门诊成本为18至87欧元/患者/30天,平均住院成本为1026至9083欧元/病例。根据计算类型的不同,生物制剂导致的成本数额也不同。关于直接医疗成本的数据较少,为82至618欧元/患者/30天,直接非医疗成本为63至84欧元/患者/30天,间接成本为463至3493欧元/患者/30天。总成本约为533欧元/患者/30天,按一年计算为6485欧元/患者。
首次有可能对德国IBD的现有医疗成本进行比较。目前的研究在IBD的方法和研究人群方面具有很大的异质性。根据总体情况,总成本高达6485欧元/患者/年。